Results 241 to 250 of about 114,032 (309)

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma. [PDF]

Future Oncol
Johnson NA, Zinzani PL, Domingo-Domenech E, Brody J, Kline J, Shah BD, Mehta AN, Ghesquieres H, Savage KJ, Barr PM, Santoro A, Ferrari S, Cunningham D, Collins GP, Fanale M, Krajewski J, Akyol A, Crowe R, Wen R, Kuruvilla J.   +19 more
europepmc   +1 more source

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. [PDF]

Blood Cancer J
Domingo-Domènech E, Pro B, Illidge T, Horwitz S, Trumper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Kim WS, Feldman T, Choi I, Gritti G, Belada D, Shustov A, Illes A, Zinzani PL, Hüttmann A, Trneny M, Le Gouill S, Jagadeesh D, Friedberg JW, Little M, Dong C, Fanale M, Fenton K, Savage KJ.   +26 more
europepmc   +1 more source

Editorial: Primary and secondary hyperparathyroidism: from etiology to treatment. [PDF]

Front Endocrinol (Lausanne)
Alesina PF, Donatini G, Medas F.
europepmc   +1 more source

Pier

, 1993
openaire   +1 more source

Correction to: A tale of two MADs: a case series. [PDF]

Eur Heart J Case Rep
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

ISEV2026 Abstract Book

Journal of Extracellular Vesicles, Volume 15, Issue S1, June 2026.
wiley   +1 more source